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Cancer patients frequently experience psychological problems related to reactions of  cancer 
diagnosis, cancer type, treatment effects, recurrence, fear of  end-of-life, survivorship, and 
financial burden. Psychological assessment has been integrated into cancer care in some 
countries, but there is limited knowledge about the practice in Rwanda. 
Objective
To assess the prevalence and associated factors of  anxiety and depression among patients 
with cancer attending a private referral hospital in Rwanda. 
Methods 
A descriptive cross-sectional study design was used with the Hospital Anxiety and Depression 
Scale (HADS) instrument to assess cancer patients. A probability systematic random sampling 
technique was used to recruit 96 patients. Data were analysed using descriptive statistics to 
determine the association of  variables with anxiety and depression.
Results 
The majority of  cancer patients had depression (67.7%) and anxiety (52.1%). Anxiety was 
associated with employment status (p=0.02), cancer stage (p=0.02), weight loss (p=0.00) and 
depression (p=0.00). Depression was associated with cancer stage (p=0.02), pain (p=0.03), 
weight loss (p= 0.03), cancer treatment (p=0.02) and anxiety (p=0.001). 
Conclusion: Anxiety and depression were reported in over half  of  the study population 
indicating a need to create and integrate psycho-oncology into standard oncology care.
Rwanda J Med Health Sci 2019;2(2):118-125. 
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Background 
Anxiety and depression are common complications of  
cancer often neglected.[1] Cancer is a feared diagnosis, 
and cancer patients demonstrate a higher tendency for 
psychological and emotional stress compared to the 
general population.[2] A recent clinical practice review 
reported that depression affects about 20%, and anxiety 
about 10% of  cancer patients, compared to 5% and 7% 
in the general population.[1]
A higher prevalence of  anxiety and depressionis related to 
reactions to the cancer diagnosis, the cancer type, treatment 
and side effects, recurrence, fear of  end-of-life care, and 
survivorship.[1,3,4] Although anxiety and depression are 
common, they are not well-recognised cancer complications, 
yet they cause a reduction in the quality of  life and survival, 
treatment compliance, and increase cost.[1,5]
In 2012, the global prevalence of  cancer cases was 14.1 
million and was estimated to increase to 21.6 million 
by 2030, which will significantly affect cancer care and 
the number of  required health care providers.[1] The 
highest increase is expected to be in low-and-middle-
income countries (LMIC), where non-communicable 
diseases (NCDs) are on the rise.[6] Cancer patients 
often feel that their emotional needs are not meet as 
much as their physical needs.[4-6] Though, according to 
the America Cancer Society, those experiencing anxiety 
and depression can nearly always be helped.[6]
Many countries have recently integrated psycho-oncology 
into cancer care using a multi-disciplinary approach, 
including psychological and lifestyle support.[1,6] 
Psycho-oncology is the psychological, social, behavioural, 
and ethical aspects of  cancer care and focuses on the 
well being of  the patient and family.[5-6] Many high-
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resource countries have integrated psychological and 
social support with the involvement of  oncology nurses, 
social workers, psychologists and psychiatrists in order 
to prevent and manage psychosocial issues arising with 
cancer care.[7] Most low-resource countries have not 
yet established psychological support,[8] though, in 
Rwanda, the Butaro Cancer Center of  Excellence offers 
mental and social support to improve the quality of  life 
for their cancer patients.[9]
Risk factors of  anxiety and depression among cancer 
patients are not well recognised and associated with a 
reduced quality of  life and survival.[1] Anxiety disorders 
appear to be related to performance status, whereas 
depressive states are associated with age, pain, and 
performance status.[10] Women with cancer are more at 
risk for anxiety and depression,[11] especially those with 
breast and gynaecological cancers, or a history of  anxiety 
and depression.[12] Cancer patients over age 40, Christian, 
and those who have not yet started cancer treatment are 
more at risk of  anxiety,[12] or depression,[13] compared 
to post-surgical patients.[13] Type of  cancer treatment 
is a significant factor for depression.[13] Other factors 
associated with anxiety and depression include the 
presence of  cancer in the family, educational level, the 
severity of  pain,[14] low socio-economic level,[15] and 
inadequate social support.[16]
In Rwanda, the Government and Non-Government 
Organizations (NGOs) have improved the medical 
management of  cancer through awareness and screening 
programs,[17] but few have a psychological support 
component to the program. There is also limited research on 
the topic in Rwanda. This study was conducted to address the 
paucity of  research related to the psychological conditions 
of  cancer patients in Rwanda. The purpose of  the study was 
to assess the prevalence of  anxiety and depression, and its 
associated factors among cancer patients who attended an 
oncology unit at a referral hospital in Kigali. 
Methods
Design
A descriptive cross-sectional study was conducted in 
the Oncology Department in one of  Rwanda’s four 
referral hospitals. Data were collected during weekdays 
from 3 April to 12 May 2017. 
Participants’ recruitment
Participants aged 18 years or older, with a cancer 
diagnosis at any stage, and on curative or palliative care, 
were included. Cancer survivors, or those with cancer 
and less than 18 years, were excluded. The sample frame 
consisted of  patients scheduled for chemotherapy, pre-
chemotherapy, laboratory investigation, or consultation 
during the scheduled data collection period. Using 
Cochran formula, a sample size of  96 was calculated 
using a confidence level of  95% and a significance 
level of  0.05. The study used a systematic random 
sampling technique, an equiprobability method with a 
K=4 (sampling interval) calculated by dividing the total 
population (333) by the sample size (n = 96).
Measures 
The questionnaire consisted of  three sections that 
included sociodemographic information, cancer clinical 
characteristics and treatment, and the Hospital Anxiety 
and Depression Scale (HADS) anxiety scale. Zigmond 
and Snaith developed the HADS.[18] The HADS is 
a valid and reliable instrument, which was originally 
designed to assess psychiatric conditions (anxiety 
and depression) in general medical settings and not 
psychiatric clinics.[18] Zigmond and Snaith were careful 
to separate the emotional concepts from physical illness, 
and therefore the reliability score demonstrated it was 
related to psychological issues and not a biological 
illness.[19] Cronbach’s alpha was 0.82.[19]
Section 1: Sociodemographic information and a history 
of  mental disorder (7 items)
Section 2: Cancer clinical characteristics and treatment 
(11 items)
Section 3: The Hospital Anxiety and Depression Scale 
(HADS) anxiety scale (14 items)
The HADS instrument consists of  alternating seven 
general anxiety items (1,3,5,7,9,11,13) with seven 
depression items (2,4,6,8,10,12,14). The HADS was 
scored on a four-point Likert scale ranging from zero 
to three. The first item on the general anxiety scale ‘I 
feel tense or wound-up’, offers the following responses: 
‘most of  the time, ’ ‘very often’, ‘from time to time/
occasionally’ and ‘not at all’ which are scored by 3, 2, 1 
and 0 respectively. Depression was scored in the same 
manner, for example, item 2 is ‘I still enjoy the things I 
used to enjoy’, and the responses include: ‘definitely as 
much’, ‘not quite so much, ‘only a little’ and ‘hardly at all’. 
These responses also are scored by 0,1,2,3 respectively.[20] 
Responses to the items were based on how the participants 
have been feeling in the preceding week as recommended 
by the original author of  the instrument.[18]
The item scores were added to give subscale scores from 
0 to 21. Higher scores indicate more depression and, or, 
anxiety. The total score would then be defined as one 
of  four categories for both anxiety and depression: [21]
	No case (0-7) without clinical symptoms 
	Mild (8-10) doubtful or suspicious cases of  anxiety 
or depression 
	Moderate (11-21) definite cases or symptomatic 
anxiety or depression
The final instrument was translated in Kinyarwanda the 
local language to reflect terms with the same meaning as 
the original scale items. Two clinical psychologists and 
two linguistic experts reviewed the translated version. A 
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pilot test was conducted on nine cancer patients, who 
did not appear in the final sample, in order to test the 
feasibility of  the instrument.
Data collection
The sample frame consisted of  patients who attended a 
consultation, pre-chemotherapy laboratory exams, and 
chemotherapy. A list of  codes of  selected patients was 
given to the nurse of  the oncology unit, and they advised 
the patients about the study and the presence of  a study 
investigator. While waiting for their consultation and 
treatment, the investigator approached a patient based on 
the list above. The purpose of  the study was explained, and 
the letter of  information was given to the patients. Those 
who accepted to participate signed the consent form 
knowing that their information was anonymous, and they 
could withdraw from the study. The data collection tool 
was a self-reported questionnaire, but verbal or written 
assistance with a question was given when needed. The 
questionnaire took 10 to 15 minutes to complete.
Data analysis
The prevalence of  anxiety and depression was estimated 
using frequencies. A Chi-square test was used to measure 
the association between social demographic variables 
and anxiety and depression prevalence, and medical and 
cancer-related variables among cancer patients. Data 
was entered and analysed by using SPSS (version 21). 
Ethical considerations 
The University of  Rwanda, College of  Medicine and 
Health Science, Institutional Review Board, and the 
ethics committee at the referral hospital approved the 
study. All patients signed a consent form before data 
collection.  
Results
The study results indicated that the majority of  
participants were female (58.3%), married (73%), and 
with health insurance (91.7%) (table 1). The mean age 
was 52 years, with a range of  18-78 years. The majority 
was not employed (55.2%), as many were retired or 
experienced cancer-related disability. Nearly one third 
(30.2%) had breast cancer, which was the most common 
type among study participants. The patients’ records 
showed that half  of  the cancer patients (49.4%) had 
stage three and four cancer, and most were accessing 
treatment (93.8%) and receiving chemotherapy (92.1%).
Table 1. Socio-Demographic Characteristics (n = 96)
______________________________________



























The study results show that a quarter (26%) of  
participants had mild anxiety, and another quarter (26%) 
had symptomatic anxiety (table 2). A third (32.3%) of  
participants had mild depression, and a third (34.4%)
had symptomatic depression. The prevalence of  anxiety 
and depression included all participants who have the 
score ≥ 8 (mild and symptomatic cases); therefore, over 
half  (52.1%) had anxiety, and two-thirds (67.7%) of  the 
study population had depression.
Significant association of  anxiety and depression 
The data indicated that there were four significant 
statistical associations with anxiety and five with 
depression (table 3). For demographic characteristics, 
the results showed that anxiety was associated with 
employment status (p=0.02). Cancer and clinical 
characteristics associated with anxiety included cancer 
stage (p=0.02), weight loss (p=0.00), fatigue (p=0.01) 
and depression (p=0.02). There was also a significant 
statistical association between depression and weight 
loss (p=0.02), pain (p=0.03), fatigue (p=0.02), cancer 
treatment (p=0.04) and anxiety (p=0.02). Gender, age, 
marital status, the person living with, cancer types and 
duration after diagnosis had no statistical significance.
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Table 3. Analysis showing the Socio-Demographic Characteristics Associated with Anxiety and Depression (n = 96)
Variables  No Anxiety  Anxiety p  No depression  Depression  p
 n(%) n(%)
Gender   0.7   0.6
Male 20(50.0) 20(50.0)  14(35.0) 26 (65.0)  
Female 26(46.4) 30(43.6)  17(30.4) 39(69.6)  
Age (years)   0.1   0.4
18-35 8(72.7) 3(27.3)  5(45.5) 6(54.5)  
36-43 6(37.5) 10(62.5)  3(18.8) 13(81.3)  
44-61 23(53.5) 20(46.5)  17(39.5) 26(60.5)  
62-89 9(34.6) 17(65.4)  6(23.1) 20(76.9)  
Marital status   0.1   0.1
Single 4(80.0) 1(20.0)  3(60.0) 2(40.0)  
Married 35(50.0) 35(50.0)  23(32.9) 47(67.1)  
Cohabit 1(100) 0(0)  1(100) 0(0)  
Separated 3(50.0) 3(50.0)  0(0) 6(100)  
Widow 3(21.4) 11(78.6)  4(28.6) 10(71.4)  
Person living with   0.8   0.1
Family 41(48.8) 43(51.2)  30(35.7) 54(64.3)  
Friends 2(50.0) 2(50.0)  1(25.0) 3(75.0)  
Living alone 3(37.5) 5(62.5)  0(0) 8(100)  
Employment status   0.02   0.9
Not employed 7(26.9) 19(73.1)  7(26.9) 19(73.1)  
Employed 27(62.8) 16(37.2)  16(37.2) 27(62.8)  
Retired 5(55.6) 4(44.4)  3(33.3) 6(66.7)  
Disabled by cancer 7(39.9) 11(61.1)  5(27.8) 13(72.2)  
Health insurance   0.1   0.7
Public 40(45.5) 48(54.5) 29(33.0) 59(67.0)
Private 6(75.0) 2(25.0)  2(25.0) 6(75.0)  
History of  mental 
disorder 
No 43(47.3) 48(52.7)
 31(34.1) 60(65.9)  
Yes 3(60.0) 2(40.0)  0(0) 5(100)  
A significant association with found between anxiety 
and cancer stage (p=0.02), weight loss (p=0.00), fatigue 
(p=0.01) and depression (p=0.02) (table 4). A significant 
association was also found between depression and 
weight loss (p=0.02), pain (p=0.03), fatigue (p=0.02), 
cancer treatment (p=0.04) and anxiety (p=0.02). 
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Table 4. Analysis showing Clinical and Cancer Factors Associated with Anxiety and Depression (n = 96)
Variables No Anxiety Anxiety p No depression  Depression p
n(%) n(%)
Cancer types   0.6   0.1
Breast cancer 16(55.2) 13(44.8)  13(44.8) 16(55.2)  
Gynaecological Cancers 5(33.3) 10(66.7)  4(26.7) 11(73.3)  
GI cancers 7(38.9) 11(61.1)  2(11.1) 16(88.9)  
Prostate Cancer 7(58.8) 5(41.7)  4(33.3) 8(66.7)  
Kaposi sarcoma 1(100) 0(0)  1(100) 0(0)  
Leukaemia 1(50) 1(50)  1(50) 1(50)  
Lung cancer 2(40) 3(60)  1(20) 4(80)  
Lymphoma 3(50) 3(50)  1(1) 5(83.3)  
Rhabdomyosarcoma 1(100) 0(0)  0(0) 1(100)  
Ewing sarcoma 3(75) 1(25)  3(75) 1(25)  
Head and neck cancers 0(0) 2(100)  1(50) 1(50)  
Cancer stage   0.02   0.1
Stage II 16(66.7) 8(33.3)  11(45.8) 13(54.2)  
Stage III 22(50) 22(50)  14(31.8) 30(68.2)  
Stage IV 7(28) 18(72)  5(20) 20(80)  
Duration since diagnosis  0.7   0.5
<1 year 27(46.6) 31(53.4) 17(29.3) 41(70.7)
>1 year 19(50) 19(50)  14(36.8) 24(63.2)  
Weight loss   0.00   0.02
No 27(73) 10(270 17(45.90 20(54.1)
Yes 19(32.20 40(67.80  14(23.7) 45(76.3)  
Pain   0.2   0.03
No 5(71.4) 2(28.6)  5(71.4) 2(28.6)
Yes 41(46.1) 48(53.9)  26(29.2) 63 (70.8)  
Fatigue   0.01   0.02
No 18(69.2) 8(30.8)  15(57.7) 11(42.3)  
Yes 28(40) 42(60)  16(22.9) 54(77.1)  
Cancer treatment   0.6   0.6
No 2(33.3) 4(66.7)  1(16.7) 5(83.3)
Yes 44(48.9) 46(51.1)  30(33.3) 60(66.7)  
Treatment types 0.9 0.04
Chemotherapy 40(48.2) 43(51.8)   26(31.3) 57(68.7)  
Radiotherapy 1(50) 1(50)  0(0) 2(100)  
Hormonal therapy 2(66.7) 1(33.3)  3(100) 0(0)  
Surgery 1(50) 1(90)  1(50) 1(50)  
Nausea   0.5   0.7
No 11(61.1) 7(38.9) 5(27.8) 13(72.2)  
Yes 29(47.5) 32(52.5)  26(33.3) 52(66.7)  
Vomiting 0.1 0.09
No 20(40.8) 29(59.2) 19(40.4) 28(59.6)
Yes 26(55.3) 21(44.7) 12(24.5) 37(75.5)
Depression
No depression 22(47.8) 24(52.2) 0.02
Depression 9(18) 41(82)
Anxiety
No anxiety  22(47.8) 24(52.2) 0.02
Anxiety  9(18) 41(82)
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Discussion
The current study results revealed that the majority of  
participants were female (58.3%), married (73%), with a 
mean age of  52 years. This sample is similar to a study 
conducted in Iran where the female occupied 52% of  
all participants, and the majority were married.[21]
Prevalence of  anxiety and depression among 
cancer patients
The current study used a cut-off  point of  ≥8 of  
the HADS instrument, which Zigmond Snaith 
recommended to identify mild and symptomatic anxiety 
or depression cases in research.[19] The results revealed 
that the depression prevalence was higher than anxiety, 
as over two-thirds had depression (67.7%), and only 
half  had anxiety (52.1%). These findings were similar 
to three studies: in China, the depression was a more 
significant psychological disorder among cancer 
patients than anxiety;[22] in Ethiopia the depression rate 
was 58.44%, higher than the anxiety rate of  51%;[23] 
and in Iran, the depression rate was 32% and anxiety 
26.7%.[21]
In contrast, two other studies used the HADS instrument 
and reported higher anxiety prevalence and lower 
depression levels among cancer patients. A Norwegian 
study indicated anxiety of  30% and a depression rate 
of  24.1%,[24] and in Nepal, the anxiety rate was 40.0%, 
and depression 28.0%.[25]
Studies from Africa are limited, though what is 
published indicates a lower prevalence of  anxiety and 
depression compared to the current study. In Nigeria, 
a study conducted among cancer patients attending a 
radiotherapy clinic revealed that 31.6% experienced 
different levels of  depression, while 36.9% had varying 
levels of  anxiety. 
Socio-demographic characteristics associated with 
anxiety and depression
There was a significant relationship between employment 
status and anxiety (p=0.02). Similarly, a study conducted 
in China demonstrated that performance status 
influenced the development of  depression and anxiety 
among cancer patients.[26] There were significant 
relationships between anxiety and depression, and older 
cancer patients in Nigeria,[10] Iran,[11] and China.[13]
In contrast, two other sociodemographic variables that 
were not associated with our study were significant in 
other studies. In Ethiopia[28] there was an association 
with gender, and others studies indicated educational 
level with anxiety and depression.[12,13]
Clinical and cancer factors associated with anxiety 
and depression
The results showed that weight loss and fatigue were 
associated with anxiety and depression, whereas fatigue 
(p=0.02) was associated with only depression. The 
previous studies reported that cancer symptoms, such 
as constant pain and change in body image, had an 
impact on the development of  depression. The pain 
was associated with depression among cancer patients 
in China,[14] Oncology, and Radiotherapy Institute 
[NORI]. Patients and Methods. 300 patients were 
interviewed from both the outpatient and inpatient 
department using The Aga Khan University Anxiety 
and Depression Scale (AKUADS) and a significant 
problem in a study in LMIC where cancer patients were 
four times more likely to suffer from a major depressive 
disorder.[22]
Cancer stage was significantly associated with anxiety, 
and these results are similar to studies conducted in 
Indonesia,[29] and Portugal.[30] The current study 
revealed that depression had a significant association 
with treatment type, especially in cancer patients 
receiving chemotherapy (68.7%), similar to another 
study.[21] Both anxiety and depression were considered 
comorbidities in the participants, which concurs with 
other studies.[27,31]
Limitations
The current study has limitations. We only used one 
study site, so the results cannot be generalised to all 
patients with cancer treated in Rwanda. A small sample 
size limited the power to predict associations between 
some variables. The study population consisted of  
patients undergoing curative and palliative care, yet their 
emotional state is likely to be significantly different. 
Since our study population was 100% patients with 
cancer, we cannot compare some situations to the 
general population, such as employment status.
Recommendations 
Hospitals need to develop policies and guidelines to 
integrate an anxiety and depression assessment into 
cancer care in Rwanda, with support from the University 
of  Rwanda MScN faculty (Oncology speciality) and 
Ministry of  Health. The presence of  depression and 
anxiety disorders and its associated factors among cancer 
patients behoves health policymakers and hospitals to 
put in place specialised cancer subunits with a focus 
on psycho-oncology. A future study could include a 
larger sample size at both urban and rural locations, 
and a comparison between curative and palliative care 
patients. 
Conclusion
The HADS instrument was an efficient screening 
tool for measuring anxiety and depression in the 
study population. The cross-sectional study findings 
indicated a high prevalence of  anxiety and depression. 
All healthcare providers caring for cancer patients, 
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including nurses and midwives, must focus not only on 
the physical parts of  cancer care but also psychosocial 
and spiritual components. Information on how to 
provide comprehensive care to cancer patients should 
begin in educational programs at the university and 
continue in clinical sites. 
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